Matthieu Schmidt1,2, Peter Schellongowski3, Nicolò Patroniti4, Fabio Silvio Taccone5, Dinis Reis Miranda6, Jean Reuter7, Helène Prodanovic8, Marc Pierrot9, Amandine Dorget2, Sunghoon Park10, Martin Balik11, Alexandre Demoule8, Ilaria Alice Crippa5, Alain Mercat9, Philipp Wohlfarth3, Romain Sonneville7, Alain Combes1,2. 1. Sorbonne Universités, UPMC University Paris 06, INSERM UMRS_1166, Institute of Cardiometabolism and Nutrition, Paris, France. 2. Medical Intensive Care Unit, Hôpital de la Pitié-Salpêtrière, Assistance Publique-Hôpitaux de Paris (AP-HP), Paris, France. 3. Department of Medicine I, Intensive Care Unit 13i2, Medical University of Vienna, Vienna, Austria. 4. School of Medicine and Surgery, University of Milan-Bicocca, Department of Emergency and Intensive Care, San Gerardo Hospital, Monza, Italy. 5. Department of Intensive Care, Hôpital Erasme-Université Libre de Bruxelles, Brussels, Belgium. 6. Department of Intensive Care, Erasmus MC-University Medical Center, Rotterdam, the Netherlands. 7. AP-HP, Bichat Hospital, Medical and Infectious Diseases Intensive Care Unit, Paris Diderot University, Sorbonne Paris Cité, INSERM/Paris Diderot University, Paris, France. 8. Sorbonne Universités, UPMC University Paris 06, INSERM, UMRS_1158 Neurophysiologie Respiratoire Expérimentale et Clinique, AP-HP, Groupe Hospitalier Pitié-Salpêtrière Charles Foix, Service de Pneumologie et Réanimation Médicale (Département "R3S"), Paris, France. 9. Service de Réanimation Médicale, Centre Hospitalier Universitaire d'Angers, Angers, France. 10. Department of Pulmonary, Allergy and Critical Care Medicine, Hallym University Sacred Heart Hospital, Anyang, Korea; and. 11. Department of Anaesthesia and Intensive Care, 1st Medical Faculty, Charles University, General University Hospital, Prague, Czech Republic.
Abstract
Rationale: Because encouraging rates for hospital and long-term survival of immunocompromised patients in ICUs have been described, these patients are more likely to receive invasive therapies, like extracorporeal membrane oxygenation (ECMO). Objectives: To report outcomes of immunocompromised patients treated with ECMO for severe acute respiratory distress syndrome (ARDS) and to identify their pre-ECMO predictors of 6-month mortality and main ECMO-related complications. Methods: Retrospective multicenter study in 10 international ICUs with high volumes of ECMO cases. Immunocompromised patients, defined as having hematological malignancies, active solid tumor, solid-organ transplant, acquired immunodeficiency syndrome, or long-term or high-dose corticosteroid or immunosuppressant use, and severe ECMO-treated ARDS, from 2008 to 2015 were included.Measurements and Main Results: We collected demographics, clinical data, ECMO-related complications, and ICU- and 6 month-outcome data for 203 patients (median Acute Physiology and Chronic Health Evaluation II score, 28 [25th-75th percentile, 20-33]; age, 51 [38-59] yr; PaO2/FiO2, 60 [50-82] mm Hg before ECMO) who fulfilled our inclusion criteria. Six-month survival was only 30%, with a respective median ECMO duration and ICU stay of 8 (5-14) and 25 (16-50) days. Patients with hematological malignancies had significantly poorer outcomes than others (log-rank P = 0.02). ECMO-related major bleeding, cannula infection, and ventilator-associated pneumonia were frequent (36%, 10%, and 50%, respectively). Multivariate analyses retained fewer than 30 days between immunodeficiency diagnosis and ECMO cannulation as being associated with lower 6-month mortality (odds ratio, 0.32 [95% confidence interval, 0.16-0.66]; P = 0.002), and lower platelet count, higher Pco2, age, and driving pressure as independent pre-ECMO predictors of 6-month mortality.Conclusions: Recently diagnosed immunodeficiency is associated with a much better prognosis in ECMO-treated severe ARDS. However, low 6-month survival of our large cohort of immunocompromised patients supports restricting ECMO to patients with realistic oncological/therapeutic prognoses, acceptable functional status, and few pre-ECMO mortality-risk factors.
Rationale: Because encouraging rates for hospital and long-term survival of immunocompromised patients in ICUs have been described, these patients are more likely to receive invasive therapies, like extracorporeal membrane oxygenation (ECMO). Objectives: To report outcomes of immunocompromised patients treated with ECMO for severe acute respiratory distress syndrome (ARDS) and to identify their pre-ECMO predictors of 6-month mortality and main ECMO-related complications. Methods: Retrospective multicenter study in 10 international ICUs with high volumes of ECMO cases. Immunocompromised patients, defined as having hematological malignancies, active solid tumor, solid-organ transplant, acquired immunodeficiency syndrome, or long-term or high-dose corticosteroid or immunosuppressant use, and severe ECMO-treated ARDS, from 2008 to 2015 were included.Measurements and Main Results: We collected demographics, clinical data, ECMO-related complications, and ICU- and 6 month-outcome data for 203 patients (median Acute Physiology and Chronic Health Evaluation II score, 28 [25th-75th percentile, 20-33]; age, 51 [38-59] yr; PaO2/FiO2, 60 [50-82] mm Hg before ECMO) who fulfilled our inclusion criteria. Six-month survival was only 30%, with a respective median ECMO duration and ICU stay of 8 (5-14) and 25 (16-50) days. Patients with hematological malignancies had significantly poorer outcomes than others (log-rank P = 0.02). ECMO-related major bleeding, cannula infection, and ventilator-associated pneumonia were frequent (36%, 10%, and 50%, respectively). Multivariate analyses retained fewer than 30 days between immunodeficiency diagnosis and ECMO cannulation as being associated with lower 6-month mortality (odds ratio, 0.32 [95% confidence interval, 0.16-0.66]; P = 0.002), and lower platelet count, higher Pco2, age, and driving pressure as independent pre-ECMO predictors of 6-month mortality.Conclusions: Recently diagnosed immunodeficiency is associated with a much better prognosis in ECMO-treated severe ARDS. However, low 6-month survival of our large cohort of immunocompromised patients supports restricting ECMO to patients with realistic oncological/therapeutic prognoses, acceptable functional status, and few pre-ECMO mortality-risk factors.
Authors: Matthieu Schmidt; Claire Stewart; Michael Bailey; Ania Nieszkowska; Joshua Kelly; Lorna Murphy; David Pilcher; D James Cooper; Carlos Scheinkestel; Vincent Pellegrino; Paul Forrest; Alain Combes; Carol Hodgson Journal: Crit Care Med Date: 2015-03 Impact factor: 7.598
Authors: Marcelo B P Amato; Maureen O Meade; Arthur S Slutsky; Laurent Brochard; Eduardo L V Costa; David A Schoenfeld; Thomas E Stewart; Matthias Briel; Daniel Talmor; Alain Mercat; Jean-Christophe M Richard; Carlos R R Carvalho; Roy G Brower Journal: N Engl J Med Date: 2015-02-19 Impact factor: 91.245
Authors: Ryan P Barbaro; Folafoluwa O Odetola; Kelley M Kidwell; Matthew L Paden; Robert H Bartlett; Matthew M Davis; Gail M Annich Journal: Am J Respir Crit Care Med Date: 2015-04-15 Impact factor: 21.405
Authors: John G Laffey; Giacomo Bellani; Tài Pham; Eddy Fan; Fabiana Madotto; Ednan K Bajwa; Laurent Brochard; Kevin Clarkson; Andres Esteban; Luciano Gattinoni; Frank van Haren; Leo M Heunks; Kiyoyasu Kurahashi; Jon Henrik Laake; Anders Larsson; Daniel F McAuley; Lia McNamee; Nicolas Nin; Haibo Qiu; Marco Ranieri; Gordon D Rubenfeld; B Taylor Thompson; Hermann Wrigge; Arthur S Slutsky; Antonio Pesenti Journal: Intensive Care Med Date: 2016-10-18 Impact factor: 17.440
Authors: Andrew Davies; Daryl Jones; Michael Bailey; John Beca; Rinaldo Bellomo; Nikki Blackwell; Paul Forrest; David Gattas; Emily Granger; Robert Herkes; Andrew Jackson; Shay McGuinness; Priya Nair; Vincent Pellegrino; Ville Pettilä; Brian Plunkett; Roger Pye; Paul Torzillo; Steve Webb; Michael Wilson; Marc Ziegenfuss Journal: JAMA Date: 2009-10-12 Impact factor: 56.272
Authors: V Marco Ranieri; Gordon D Rubenfeld; B Taylor Thompson; Niall D Ferguson; Ellen Caldwell; Eddy Fan; Luigi Camporota; Arthur S Slutsky Journal: JAMA Date: 2012-06-20 Impact factor: 56.272
Authors: Keshava Rajagopal; Steven P Keller; Bindu Akkanti; Christian Bime; Pranav Loyalka; Faisal H Cheema; Joseph B Zwischenberger; Aly El Banayosy; Federico Pappalardo; Mark S Slaughter; Marvin J Slepian Journal: Circ Heart Fail Date: 2020-05-01 Impact factor: 8.790
Authors: Jonathan Rilinger; Viviane Zotzmann; Xavier Bemtgen; Siegbert Rieg; Paul M Biever; Daniel Duerschmied; Torben Pottgiesser; Klaus Kaier; Christoph Bode; Dawid L Staudacher; Tobias Wengenmayer Journal: Artif Organs Date: 2021-05-04 Impact factor: 2.663